Friday, 29 August 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 29 August 2025
News

Blockbuster combo's new target

Posted 28 August 2025 PM

A combo of blockbusters has shown efficacy in a new indication, becoming the first regimen to improve survival for certain types of bladder cancer.

ADC Padcev, sponsored by Astellas in Australia, in combination with MSD's PD-1 inhibitor Keytruda, met the primary endpoint in the EV-303 phase 3 study as neoadjuvant and adjuvant treatment versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (12)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (6)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.